A Randomised, Double Blind, Three-Arm, Single Dose, Parallel Study To Compare the Pharmacokinetics, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar Drug), US Licenced Avastin® and EU Approved Avastin® in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2018
At a glance
- Drugs Bevacizumab (Primary)
- Indications Colorectal cancer; Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors mAbxience
- 12 Nov 2018 Planned number of patients changed from 99 to 114.
- 11 Oct 2018 Planned End Date changed from 1 May 2018 to 1 Mar 2019.
- 11 Oct 2018 Planned primary completion date changed from 1 May 2018 to 1 Mar 2019.